Coherus BioSciences (NASDAQ: CHRS) is a biotechnology company focused on developing and selling treatments for cancer. The company's commercial strategy centers on its drug LOQTORZI, which is used to treat nasopharyngeal cancer. Coherus BioSciences uses this drug both as a direct source of revenue and as a component in combination with other potential cancer therapies in its development pipeline.
On May 11, 2026, Coherus BioSciences reported its quarterly financial results. The company announced an earnings per share (EPS) of -$0.27. EPS shows how much profit or loss a company makes for each share of its stock. This result narrowly missed the average analyst expectation of a -$0.26 loss per share.
The company's total revenue for the quarter was $12.31 million, which also fell short of the analyst estimate of $14.22 million. This revenue, however, marks an increase from the $7.60 million reported in the same quarter a year ago. The revenue growth is driven by its main product, LOQTORZI, which generated net sales of $11.80 million.
Despite missing current estimates, the company expects revenue from LOQTORZI to continue growing through 2026. Chief Executive Officer Dennis Lanfear projects that revenue could reach about $15.00 million per quarter sometime in 2026. The company also maintains a solid financial position, ending the quarter with $167.00 million in cash and cash equivalents.
